Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Demand for Cancer Treatment Remains High Despite Improving Survivability Rates

Deaths related to cancer dropped by 27% in the past quarter-century, meaning that 2.6 million fewer people died due to cancer during that time period, according to a report by the American Cancer Society....

ABIO : 0.47 (-6.86%)
SESN : 0.83 (+2.47%)
NAVB : 0.17 (+13.33%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0179 (-5.79%)
CGIX : 0.25 (unch)
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public...

CGIX : 0.25 (unch)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders...

CGIX : 0.25 (unch)
Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten...

CGIX : 0.25 (unch)
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer...

CGIX : 0.25 (unch)
Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of William Finger...

CGIX : 0.25 (unch)
Cancer Genetics Terminates Proposed Merger with NovellusDx

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it has terminated...

CGIX : 0.25 (unch)
Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics

NEW YORK, NY / ACCESSWIRE / December 14, 2018 / Biotech stocks Adial Pharmaceuticals and Cancer Genetics were exploding in Thursday's session. Adial moved higher on news that the company is considering...

ADIL : 3.97 (+17.80%)
CGIX : 0.25 (unch)
Innovative Competition Aims to Catalyze New Direction in Breast Cancer Research

Despite decades of advancement in treatment research, people continue to be diagnosed with breast cancer at astounding rates - rates that have remained essentially unchanged over the past...

CGIX : 0.25 (unch)
Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates

Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CGIX : 0.25 (unch)
Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating...

CGIX : 0.25 (unch)
Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief...

CGIX : 0.25 (unch)
Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CGIX : 0.25 (unch)
Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin(R) Test in China

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive...

CGIX : 0.25 (unch)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders...

CGIX : 0.25 (unch)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) and Lead Plaintiff Deadline - June 4, 2018

NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc.("Cancer Genetics" or the "Company") (NASDAQ:...

CGIX : 0.25 (unch)
DEADLINE ALERT: Shareholder Class Action Filed Against Cancer Genetics, Inc. - CGIX

RADNOR, PA / ACCESSWIRE / May 15, 2018 / Kaskela Law LLC reminds Cancer Genetics, Inc. (NASDAQ: CGIX) ("Cancer Genetics" or the "Company") shareholders that a class action lawsuit has been filed on behalf...

CGIX : 0.25 (unch)
Cancer Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Cancer Genetics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time.

CGIX : 0.25 (unch)
Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced financial and operating results for the first quarter...

CGIX : 0.25 (unch)
Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the first...

CGIX : 0.25 (unch)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX +0.04
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar